control Oral ingestion IV EudraCT2006-003564-57 TNF-α antibody vs. control Subcutaneous injection II EudraCT2010-023830-22NCT01640457 Autologous disc chondrocyte transplantation vs. control Intradiscal injection I, II EudraCT2010-018335-17 Autologous mesenchymal stem cells Intradiscal injection I,...
III-IV. Medium potencysBetamethasone valerateCream, foam, lotion, ointment0.1 Clocortolone pivalateCream0.1 DesoximetasoneCream0.05 Fluocinolone acetonideCream, ointment0.025 FlurandrenolideCream, ointment0.05 Fluticasone propionateCream0.05 Fluticasone propionateOintment0.005 ...
(Patentee), Utility model DE 20201 018594 U1, Auxiliary Request I-IV (marked-up) dated and as filed Jul. 1, 2020, and English translation, 17 pages. German Utility Model Cancellation Proceedings, Dr. Falk Pharma GmbH (Plaintiff) vs. Adare Development I, L.P. (Patentee), Utility ...
Although additional subgroup analysis may lead to similar results to those of our study because more than 50% of patients in both studies had a pneumonia severity index [5] rating of IV or V [1,3], the target population for corticosteroid treatment should be precisely identified. Moreover, ...
Grade II GVHD occurred in 16 patients, grade III in 11 patients, and grade IV in five. Organ involvements are shown in Table 1. With the development of ≥ grade II GVHD, patients received prednisolone (2 mg/kg) as first-line therapy (this dose was increased to 3 to 5 mg/kg for ...
We examined the sleep-EEG (including conventional and spectral EEG analysis) in 9 female patients with relapsing鈥搑emitting MS (and no psychiatric disorder) just prior to and on days 2 and 10 of high dose corticosteroid treatment (500 mg/day methylprednisolone given IV for 5 days, then PO ...
In fact, there have been cases where symptoms resolved when switching from IV to oral administration. Additionally, although the evidence is contradictory, Ogyu et al. found that patients who received IV methylprednisolone had a higher risk of developing neuropsychiatric effects [77]. No certain ...